Esketamine for depression: all studies (page 9)

Intranasal Esketamine Versus Other Pharmacological Strategies in Treatment-Resistant Depression with High Suicide Risk: A Six-Month Naturalistic Study.

Clinics and practice June 12, 2026 Ana María De Granda-Beltrán, Alejandro Porras-Segovia, Daniel Núñez-arias et al.

Background: Treatment-resistant depression (TRD) poses a major clinical challenge, particularly when accompanied by suicidal behavior. Intranasal esketamine has demonstrated rapid antidepressant effects in TRD, but real-world comparative evidence remains limited. Methods: We conducted a six-month naturalistic prospective cohort study in two Spanish mental health centers, including 62 TRD...

DOI: 10.3390/clinpract16060110 Full text Esketamine Treatment-resistant depression Naturalistic study Suicidal behavior

Predicting changes in depressive symptomatology following oral esketamine treatment in treatment-resistant depression: A machine-learning approach.

Journal of Psychiatric Research June 12, 2026 Juliana Lima Constantino, Tobias Stephan Freimann, Jens H van Dalfsen et al.

Oral esketamine is a potentially effective and well-tolerated treatment for treatment-resistant depression (TRD). However, around 50% of TRD individuals treated with oral esketamine do not achieve response, and this variation in response may be accounted for by interindividual differences between patients. Efforts to develop effective and personalized depression treatment strategies are...

DOI: 10.1016/j.jpsychires.2026.06.013 Full text Esketamine Major depressive disorder Treatment-resistant depression Antidepressants +1

Functional outcomes with esketamine in treatment-resistant depression: A 6-month multicenter real-world study.

European Psychiatry June 10, 2026 Riccardo Guglielmo, Miriam Olivola, Alberto Inuggi et al.

Esketamine has demonstrated efficacy in treatment-resistant depression (TRD), but medium-term real-world functional outcomes remain understudied. This study described 6-month depressive symptoms and functional trajectories during routine esketamine treatment, focusing on functional outcomes and remission correlates. In this prospective multicenter study, 60 patients with TRD initiating...

DOI: 10.1192/j.eurpsy.2026.12233 Full text Esketamine Treatment-resistant depression Functional remission Long-term outcomes +1

[Intravenous Subnarcotic Ketamine Infusions for Treatment-Resistant Depression: Historical Development, Comparison with Esketamine Nasalspray, and Prospects].

Fortschritte der Neurologie · Psychiatrie June 8, 2026 Udo Bonnet, Norbert Scherbaum, Georg Juckel et al.

Introduction: Esketamine nasal spray (EN) has been approved in Germany since 2021 for the treatment of treatment-resistant depression (TRD). Historically, the development of EN resulted from the positive results of randomized clinical trials on the off-label use of subnarcotic ketamine infusions (SKI) for TRD. How effective, tolerable, and safe is off-label SKI compared to EN? Methods: Narrativ...

DOI: 10.1055/a-2846-4275

Prescribing bias and adverse outcomes of esketamine in major depression comorbid substance.

Journal of Affective Disorders June 8, 2026 Dian‐jeng Li, Tien-Wei Hsu, Te-Chang Changchien et al.

Little is known about esketamine's effectiveness for patients with major depressive disorder (MDD) comorbid substance use disorders (SUD). We conducted a retrospective cohort study using the TriNetX US Collaborative Network, including adults aged ≥18 years with MDD. Three propensity-score-matched (1:1) cohorts were defined based on treatment: esketamine, antidepressant-only, and repetitive...

DOI: 10.1016/j.jad.2026.122106 Full text Esketamine Major depressive disorder Substance use disorder Mortality +1

Comparing transcranial magnetic stimulation and esketamine treatment response trajectories in resistant depression.

Journal of Affective Disorders June 7, 2026 Lindsay L Benster, Jordan N Kohn, Benjamin Wade et al.

Repetitive transcranial magnetic stimulation (rTMS) and intranasal esketamine are FDA-approved for treatment-resistant depression (TRD), yet comparative real-world data on response trajectories and predictors of outcomes remain limited. A retrospective analysis was performed using electronic medical records from UC San Diego Health. Adults with TRD treated with rTMS (n = 279) or intranasal...

DOI: 10.1016/j.jad.2026.122107 Full text Esketamine Treatment-resistant depression Rtms

Patient reported outcomes of MDD patients treated with esketamine nasal spray in real world practice: the French ELLIPSE study

European Psychiatry June 1, 2026 P.-M. Llorca, Ludovic Samalin, Emilie Olié et al.

Introduction: Esketamine nasal spray (ESK) was approved in 2019 in Europe for adults with Treatment-Resistant Depression (TRD), defined as inadequate response to at least two different antidepressants during the current moderate to severe depressive episode Objectives: To assess patient-reported outcomes related to symptomatology, quality of life, and occupational impairment over 12 months...

DOI: 10.1192/j.eurpsy.2026.10194

Personality Disorders and Clinical Response to Intranasal Esketamine in Treatment-Resistant Depression: Trajectories, Modulations, and Psychopathological Reflections

European Psychiatry June 1, 2026 V. Casati, Kevin la Monica, Mauro Angeletti et al.

Introduction Intranasal esketamine has emerged as an innovative treatment for TRD due to its rapid antidepressant effects. However, the clinical response is heterogeneous, and growing evidence suggests that comorbid personality disorders (PDs) may significantly shape treatment outcomes. Although PDs are frequently diagnosed in TRD patients, little is known about their differential influence on...

DOI: 10.1192/j.eurpsy.2026.10617 Full text

Like Stepping Outside the Noise: Narrative Experiences of Esketamine-Induced Dissociation in Patients with Treatment-Resistant Depression

European Psychiatry June 1, 2026 Giada Versaci, Miriam Olivola, Kevin la Monica et al.

Introduction Esketamine-induced dissociation is a transient, pharmacologically mediated alteration in consciousness, often distinct from pathological dissociation. While not required for clinical improvement, these states may engage neural circuits implicated in therapeutic change. Objectives This study explores patients’ lived experiences of dissociation as potentially meaningful transitional...

DOI: 10.1192/j.eurpsy.2026.10616 Full text

Ketamine/esketamine pharmacotherapy for treatment of anxiety disorders and anxiety symptoms in depression: Systematic review.

Journal of Psychopharmacology June 2026 Vasilios G Masdrakis, Zoe Tebbs, Vasilios Natsis et al.

Ketamine and esketamine ("es/ketamine") treatment protocols have been investigated in patients' samples with treatment-refractory anxiety disorders. We systematically reviewed publications in which es/ketamine was used to treat anxiety symptoms in the context of either Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) anxiety disorders or treatment-resistant...

DOI: 10.1177/02698811251389583 Full text Esketamine Anxiety disorders Anxious depression Treatment-refractory anxiety